Trial reportBritish journal of clinical pharmacology2002
No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.
Trial report in British journal of clinical pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 60 citations in OpenAlex.
- Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study.International journal of hypertension · 2020Article
- The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Frontiers in endocrinology · 2017Review
- Renal impairment, hypertension and plasma urotensin II.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2011Article
- The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.British journal of clinical pharmacology · 2009Article
- State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells.Peptides · 2008Article
- Urotensin II in cardiovascular regulation.Vascular health and risk management · 2008Review
- Therapeutic potential of blockade of the urotensin II system in systemic hypertension.Current hypertension reports · 2007Review
- Role of urotensin II and its receptor in health and disease.Journal of anesthesia · 2007Review
- Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation.British journal of pharmacology · 2006Article
- In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).British journal of pharmacology · 2006Article
- Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.British journal of pharmacology · 2005Article
- Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response.British journal of pharmacology · 2004Article
- Urotensin-II: a novel systemic hypertensive factor in the cat.Naunyn-Schmiedeberg's archives of pharmacology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn rodent and primate studies, urotensin II is an extremely potent vasoconstrictor peptide with effects in the central aortic and arterial vasculature as well as on cardiac function. The aim of the present study was to assess systemic haemodynamic responses to intravenous urotensin II infusion in humans.
methodsIn 10 healthy male volunteers, intravenous urotensin II (3, 30 and 300 pmol min-1) and saline placebo were given on separate occasions in a single-blind randomized manner. Systemic haemodynamics and arterial stiffness were assessed by sphygmomanometry, transthoracic bioimpedance, and pulse wave analysis. Plasma urotensin II immuno-reactivity was measured by radio-immunoassay.
resultsIntravenous urotensin II infusions were well tolerated with no adverse clinical effects and no electrocardiographic changes. Circulating plasma urotensin II immuno-reactivity increased from baseline of 16 +/- 1 to 1460 +/- 82 pmol l-1 (mean +/- s.e. mean) during infusion of urotensin II at 300 pmol min-1 (P < 0.001). However, there were no significant placebo adjusted changes in heart rate (95% confidence intervals: -3.6, + 4.4 min-1), mean arterial pressure (-5.8, + 1.7 mmHg) or cardiac index (-0.1, + 0.4 l min-1 m-2). There were also no changes in augmentation index (-4.1, + 5.2%) or pulse wave velocity (-1.3, + 0.3 m s-1).
conclusionsIntravenous urotensin II infusion did not affect systemic haemodynamics or arterial stiffness, despite achieving an approximately 100-fold increase in plasma immuno-reactivity. We conclude that urotensin II is unlikely to have a physiological role in the short term regulation of vascular tone or blood pressure in man. Further confirmatory studies with urotensin II receptor antagonists are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.